EyePoint Pharmaceuticals Q2 EPS $(0.61) Misses $0.41 Estimate, Sales $9.11M Which May Not Compare To $79.03M Estimate
Portfolio Pulse from Benzinga Newsdesk
EyePoint Pharmaceuticals reported Q2 losses of $(0.61) per share, missing the analyst consensus estimate of $0.41 by 248.78%. This is a 17.31% decrease over losses from the same period last year. The company also reported quarterly sales of $9.11 million, missing the analyst consensus estimate of $79.03 million by 88.48%. This is a 21.27% decrease over sales from the same period last year.
August 04, 2023 | 10:56 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
EyePoint Pharmaceuticals reported a significant miss on both earnings and sales for Q2. The company's losses per share and sales were both down YoY.
EyePoint Pharmaceuticals reported a significant miss on both earnings and sales for Q2, which is likely to negatively impact investor sentiment and potentially the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100